The use of interval-compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumor
- 18 July 2020
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 67 (10), e28559
- https://doi.org/10.1002/pbc.28559
Abstract
Background Desmoplastic small round cell tumor (DSRCT) is a rare aggressive sarcoma that affects children and young adults, and portends poor outcomes despite intensive multimodal treatment approaches. We report toxicity, response, and outcomes of patients with DSRCT treated with the addition of vincristine, irinotecan, and temozolomide (VIT) to interval-compressed chemotherapy as per Children's Oncology Group ARST08P1. Methods All newly diagnosed pediatric patients with DSRCT treated at Dana-Farber Cancer Institute and Boston Children's Hospital between 2014 and 2019 as per ARST08P1, Arm P2 with replacement of VAC cycles with VIT, were identified. Medical records were reviewed for clinical and disease characteristics, and treatment response and outcomes. Results Six patients were treated as per the above regimen. Median age at diagnosis was 15.1 years (range 3.2-16.4) and five patients were male. Five patients had abdominal primary tumors, of which one had exclusively intraabdominal and four had extraabdominal metastases. Two initial cycles of VIT were well tolerated with nausea, vomiting, diarrhea, and constipation as the most common adverse events. Overall response rate defined as partial or complete response after two initial cycles of VIT was 50%. For local control, all patients had surgical resection followed by radiotherapy, and two patients received hyperthermic intraperitoneal chemotherapy at the time of surgery. Of the four patients who have completed therapy to date, three remain disease-free with median follow-up time of 46.7 months. Conclusions The addition of VIT to interval-compressed chemotherapy is tolerable and active in DSRCT, with activity warranting additional investigation.Keywords
This publication has 40 references indexed in Scilit:
- A uniform residual tumor (R) classificationCancer, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal Of Cancer, 2009
- Outpatient and Home Chemotherapy with Novel Local Control Strategies in Desmoplastic Small Round Cell TumorSarcoma, 2008
- The feasibility and outcome of nephron‐sparing surgery for children with bilateral Wilms tumorCancer, 2008
- Reducing irinotecan‐associated diarrhea in childrenPediatric Blood & Cancer, 2007
- Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high‐risk sarcomasCancer, 2006
- Cefixime Allows Greater Dose Escalation of Oral Irinotecan: A Phase I Study in Pediatric Patients With Refractory Solid TumorsJournal of Clinical Oncology, 2006
- Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcomaCancer, 2005
- Results of multimodal treatment for desmoplastic small round cell tumorsJournal of Pediatric Surgery, 2005
- Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studiesCMAJ : Canadian Medical Association Journal, 2004